Magnetic resonance features in advanced retinoblastoma – what a paediatric radiologist needs to know
- Open Access
- 01.05.2025
- Review
Abstract
Introduction
Retinoblastoma staging and its implication on management
American Joint Committee on Cancer Clinical staging 8th edition, 2017 [4] | International Classification for Intraocular Retinoblastoma group (Shields, 2006) [5] | Recommended treatment |
|---|---|---|
cT1 Intra-retinal tumour(s) with subretinal fluid ≤ 5 mm from base of any tumour | ||
cT1a Tumours ≤ 3 mm and further than 1.5 mm from disc and fovea | A, > 3 mm to fovea or B, 1.5 to 3 mm | For ICRB group A or B: • Laser coagulation • Thermotherapy • Cryotherapy • Brachytherapy |
cT1b Tumours > 3 mm or closer than 1.5 mm from disc or fovea | B, ≤ 3 mm or C, 3 to 5 mm | |
cT2 Intraocular tumour(s) with retinal detachment, vitreous seeding, or subretinal seeding | ||
cT2a Subretinal fluid > 5 mm from the base of any tumour | C, or E, tumour > 50% of eye volume | For ICRB group C: • Systemic chemotherapy • Intra-arterial chemotherapy • Intra-vitreal chemotherapy |
cT2b Vitreous seeding and/or subretinal seeding | C, ≤ 3 mm or D, > 3 mm or E, tumour > 50% of eye volume | |
cT3 Advanced intraocular tumour(s) | ||
cT3a Phthisis or pre-phthisis bulbi | E | For ICRB group D or E: • Systemic chemotherapy • Intra-arterial chemotherapy • Intra-vitreal chemotherapy • Surgical enucleation • Adjuvant systemic chemotherapy in selected high-risk cases |
cT3b Tumour invasion of choroid, pars plana, ciliary body, lens, zonules, iris, or anterior chamber | E | |
cT3c Raised intraocular pressure with neovascularization and/or buphthalmos | E | |
cT3 d Hyphaema and/or massive vitreous haemorrhage | E | |
cT3e Aseptic orbital cellulitis | E | |
cT4 Extraocular tumour(s) involving orbit, including optic nerve | ||
cT4a Radiologic evidence of retrobulbar optic nerve involvement or thickening of optic nerve or involvement of orbital tissues cT4b Extraocular tumour clinically evident with proptosis and/or an orbital mass | ||
Magnetic resonance imaging for retinoblastoma staging
Sequence | Plane | Fat saturation | Section thickness | Repetition time (ms) | Time to echo (ms) | Matrix | Pixel size (mm) | Main use |
|---|---|---|---|---|---|---|---|---|
Orbit | ||||||||
3-D T2 weighted | Axial | No | 0.3 mm | 1400 | 156 | 512 × 512 | 0.3 × 0.3 | For evaluation of vitreous, subretinal seeding and anterior segment invasion |
T2 weighted | Oblique sagittal | Yes | 2 mm | 3,000 | 75 | 608 × 608 | 0.2 × 0.2 | For evaluation of vitreous, subretinal seeding and anterior segment invasion |
T1 weighted | Axial | Yes | 2 mm | 539 | 11 | 608 × 608 | 0.2 × 0.2 | For evaluation of vitreous haemorrhage and retinal detachment |
T1 weighted | Oblique sagittal | No | 2 mm | 600 | 7.3 | 544 × 544 | 0.3 × 0.3 | For evaluation of vitreous haemorrhage and retinal detachment |
3-D contrast-enhanced T1 weighted | Sagittal | Yes | 0.3 mm | 550 | 14 | 385 × 385 | 0.3 × 0.3 | For evaluation of choroidal invasion, iris neovascularization, aseptic cellulitis and post-laminar optic nerve invasion |
Contrast-enhanced T1 weighted | Oblique sagittal | Yes | 2 mm | 558 | 7.3 | 544 × 544 | 0.3 × 0.3 | For evaluation of choroidal invasion, iris neovascularization, aseptic cellulitis and post-laminar optic nerve invasion |
Brain | ||||||||
T2 weighted | Sagittal (pineal) | No | 2 mm | 3,000 | 86 | 384 × 384 | 0.2 × 0.2 | For identification of any synchronous suprasellar and pineal tumour |
Diffusion-weighted imaging | Axial | NA | 5 mm | 3,000 | 65.2 | 400 × 400 | 0.5 × 0.5 | For better tumour characterization |
3-D fluid attenuated inversion recovery | Sagittal | Yes | 0.3 mm | 5,000 | 311 | 320 × 320 | 0.3 × 0.3 | For screening of any intracranial abnormality |
Susceptibility-weighted imaging | Axial | NA | 2 mm | 30 | 20 | 288 × 252 | 0.7 × 0.7 | For better assessment of any intralesional calcifications |